NASDAQ$TXMD
TherapeuticsMD Inc · Q1 2024 earnings
Q1 2024 earnings · · After market close · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2024.
TherapeuticsMD, Inc. reported financial results for the first quarter ended March 31, 2024, focusing on pharmaceutical royalties collection after transitioning from a women's healthcare company in December 2022.
- TherapeuticsMD is now primarily focused on collecting royalties from its licensees.
- The company is no longer engaged in research and development or commercial operations.
- TherapeuticsMD is evaluating strategic alternatives, including potential acquisition, merger, or sale of assets.
- The company's future performance depends on the success of its licensees in commercializing licensed products.
Headline financials
Revenue & EPS history
TherapeuticsMD · Revenue · Quarterly
$313K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+0.4%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+0.9%
Avg return
30 days after
38%
24 / 64 earnings
Positive
+200.0%
Q1 2011
Best reaction
-27.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -3.6% | -8.3% | +4.2% | |
| Q2 2025 | -0.9% | -2.7% | -1.8% | |
| Q1 2025 | -3.9% | -2.6% | -23.0% | |
| Q4 2024 | +6.1% | +20.9% | +26.1% | |
| Q3 2024 | -1.3% | -7.9% | -17.8% | |
| Q2 2024 | -1.2% | -4.0% | +2.9% | |
| Q1 2024 | +2.5% | +6.7% | -4.8% | |
| Q1 2026 | -1.9% | +6.7% | -4.8% | |
| Q4 2023 | +1.3% | -2.6% | -18.8% | |
| Q3 2023 | +17.1% | +12.4% | +18.3% | |
| Q2 2023 | -3.0% | -5.3% | -10.9% | |
| Q1 2023 | +0.2% | -1.6% | -13.9% | |
| Q4 2022 | +0.6% | +2.0% | +7.6% | |
| Q3 2022 | -15.0% | -27.8% | +0.3% | |
| Q2 2022 | +4.1% | +8.5% | -7.2% | |
| Q1 2022 | -12.1% | +1.0% | +223.1% | |
| Q4 2021 | -27.5% | -17.5% | -17.5% | |
| Q3 2021 | -12.5% | -18.1% | -37.5% | |
| Q2 2021 | -4.1% | -3.1% | -18.4% | |
| Q1 2021 | -14.8% | -18.7% | -5.5% | |
| Q4 2020 | +0.7% | -5.5% | -4.1% | |
| Q3 2020 | +10.7% | +0.8% | -4.9% | |
| Q2 2020 | -18.5% | -24.4% | -31.2% | |
| Q1 2020 | -5.8% | -5.8% | -15.1% | |
| Q4 2019 | -14.2% | -22.9% | -57.9% | |
| Q3 2019 | +4.1% | +5.2% | -10.3% | |
| Q2 2019 | +17.7% | +61.5% | +44.3% | |
| Q1 2019 | -12.8% | -20.9% | -26.8% | |
| Q4 2018 | -1.1% | +4.4% | -4.9% | |
| Q3 2018 | +6.0% | +0.4% | -3.4% | |
| Q2 2018 | -14.1% | -14.1% | +3.6% | |
| Q1 2018 | +2.2% | +4.9% | -0.7% | |
| Q4 2017 | -8.4% | -3.8% | -10.2% | |
| Q3 2017 | +27.8% | +30.0% | +33.0% | |
| Q2 2017 | -6.6% | -4.1% | +6.8% | |
| Q1 2017 | -6.4% | -6.8% | -12.2% | |
| Q4 2016 | +3.0% | +10.8% | +19.4% | |
| Q3 2016 | +0.0% | +10.5% | +19.7% | |
| Q2 2016 | +0.8% | +2.1% | -9.2% | |
| Q1 2016 | -5.8% | — | — | |
| Q4 2015 | +2.2% | — | — | |
| Q3 2015 | +2.2% | — | — | |
| Q2 2015 | -9.2% | — | — | |
| Q1 2015 | -11.6% | — | — | |
| Q4 2014 | +0.4% | — | — | |
| Q3 2014 | -15.3% | — | — | |
| Q2 2014 | +10.7% | — | — | |
| Q1 2014 | -9.0% | — | — | |
| Q4 2013 | +2.8% | — | — | |
| Q3 2013 | -10.0% | — | — | |
| Q2 2013 | -5.4% | — | — | |
| Q1 2013 | +0.4% | — | — | |
| Q4 2012 | -1.8% | — | — | |
| Q3 2012 | -8.7% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q1 2012 | -2.0% | — | — | |
| Q4 2011 | -3.6% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +200.0% | — | — | |
| Q4 2010 | -25.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro